| HOME >> BIOLOGY >> TECHNOLOGY |
STATESVILLE, N.C., June 24 /PRNewswire-FirstCall/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported record sales, earnings, and order backlog for its fiscal year ended April 30, 2009.
Net earnings for the year increased 36% to $4,247,000, or $1.66 per diluted share, up from net earnings of $3,134,000, or $1.23 per diluted share, in the prior year. Earnings benefited from higher sales volume, lower manufacturing costs and improved operational efficiencies.
Sales for the year increased 16% to $103,978,000, up from sales of $89,510,000 in the prior year. Sales from domestic operations increased to $90,250,000, up 22.0% from the prior year. Sales from international operations were $13,728,000, down 13% from the prior year. Incoming orders activity was strong throughout the year, as a healthy domestic laboratory furniture marketplace more than offset the impact of a soft Asian marketplace. The order backlog increased to a record $62.7 million at April 30, 2009, up from $60.7 million at January 31, 2009 and $58.7 million at April 30, 2008.
Net earnings for the fourth quarter were $920,000, or $0.36 per diluted share, up from net earnings of $446,000, or $0.17 per diluted share, in the prior year. Sales for the fourth quarter increased to $24,828,000, up 12% from sales of $22,116,000 in the same period of the prior year. Sales from domestic operations for the quarter were $22,954,000, up from sales of $18,015,000 in the same quarter of the prior year, while sales from international operations were $1,874,000, down from sales of $4,101,000 in the prior year.
The Company's balance sheet remains strong. Working capital increased to $18.9 million at April 30, 2009, up from $15.9 million at the end of the prior year. Cash on hand at the end of the year was $4.0 million, as compared to $4.3
'/>"/>
| SOURCE Kewaunee Scientific Corporation Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
2. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
3. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
4. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
5. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
6. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
7. Thermo Fisher Scientific to Present at Investor Conferences
8. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
9. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
10. BioLife Solutions Expands Scientific Advisory Board
11. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |